2025
X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline
Khan A, Ali D, Appelman-Dijkstra N, Carpenter T, Chaussain C, Imel E, de Beur S, Florenzano P, Abu Alrob H, Aldabagh R, Alexander R, Alsarraf F, Beck-Nielsen S, Biosse-Duplan M, Cohen-Solal M, Crowley R, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid M, Khan S, Khan A, Lehman A, Lems W, Lewiecki E, McDonnell C, Mirza R, Morgante E, Morrison A, Portale A, Rhee Y, Rush E, Siggelkow H, Tetradis S, Tosi L, Ward L, Guyatt G, Brandi M. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf170. PMID: 40243526, DOI: 10.1210/clinem/dgaf170.Peer-Reviewed Original ResearchInternational Working GroupSystematic reviewX-linked hypophosphatemiaClinical practice guidelinesPatient-important outcomesCertainty of evidenceConventional therapyNO therapyDiagnosis of XLHPatient partnersPatient societiesAbsence of fractureMultidisciplinary teamPractice guidelinesInsufficient evidenceGlobal guidelinesGRADE methodologyTreated with conventional therapyNarrative reviewRenal phosphate wastingSymptomatic adultsEffective medical therapyAdultsWorking GroupPathogenic variantsX-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline
Ali D, Carpenter T, Imel E, Ward L, Appelman-Dijkstra N, Chaussain C, de Beur S, Florenzano P, Abu Alrob H, Aldabagh R, Alexander R, Alsarraf F, Beck-Nielsen S, Biosse-Duplan M, Crowley R, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid M, Khan S, Khan A, Lehman A, Lems W, Lewiecki E, McDonnell C, Mirza R, Morgante E, Morrison A, Portale A, Rao C, Rhee Y, Rush E, Siggelkow H, Tetradis S, Tosi L, Guyatt G, Brandi M, Khan A. X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline. The Journal Of Clinical Endocrinology & Metabolism 2025, 110: 2055-2070. PMID: 39960858, PMCID: PMC12187519, DOI: 10.1210/clinem/dgaf093.Peer-Reviewed Original ResearchClinical practice guidelinesInternational Working GroupX-linked hypophosphatemiaClinical practice surveyPractice guidelinesMultidisciplinary healthcare professionalsPractice surveyManagement of "X-linked hypophosphatemiaPatient-important outcomesCertainty of evidenceCare of childrenNO therapyConventional therapyHealthcare professionalsDiagnosis of XLHPatient partnersMonitoring recommendationsTreatment of X-linked hypophosphatemiaMethodological expertsGRADE recommendationsSystematic reviewGenetic testingGRADE methodologyNarrative reviewDental complicationsManagement of Severe Hypertriglyceridemia in Pregnancy With Niacin: Reevaluating Safety and Therapeutic Benefits
Suda N, Leon-Martinez D, Peter P, Flannery C, Irani R. Management of Severe Hypertriglyceridemia in Pregnancy With Niacin: Reevaluating Safety and Therapeutic Benefits. Case Reports In Endocrinology 2025, 2025: 2644678. PMID: 39949380, PMCID: PMC11824309, DOI: 10.1155/crie/2644678.Peer-Reviewed Original ResearchSevere hypertriglyceridemiaTG levelsAttention-deficient hyperactivity disorderManagement of severe hypertriglyceridemiaInsulin infusionSafety of niacinHistory of cholecystectomyIntravenous (IV) fluidsLow-fat dietPersonalized management approachPerceived side effectsCesarean sectionHypertriglyceridemic pancreatitisPrepregnancy BMIWeeks gestationPersistent hypertriglyceridemiaMaternal TGOmega-3 fatty acidsLong-term managementEarly deliveryPregnant womenAcute pancreatitisConventional therapyHypertriglyceridemiaInsulin regimensOutcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.
Ganguly A, Paladiya R, Ingawale S, Giri S, Abbagoni V, Thumar J. Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. Journal Of Clinical Oncology 2025, 43: 208-208. DOI: 10.1200/jco.2025.43.4_suppl.208.Peer-Reviewed Original ResearchTNT groupTotal neoadjuvant therapyLocally Advanced Rectal CancerAdvanced rectal cancerManagement of locally advanced rectal cancerTumor locationNeoadjuvant therapyConventional therapyRectal cancerCT groupPropensity score matchingLow tumorsHigh tumorNo responsePathologic response to treatmentTreating locally advanced rectal cancerResponse ratePartial response ratePathological response rateScore matchingFisher's exact testResponse to treatmentComplete responseAdjuvant treatmentUnderserved populationsSystematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia
Ali D, Mirza R, Hussein S, Alsarraf F, Alexander R, Abu Alrob H, Appelman-Dijkstra N, Biosse-Duplan M, Brandi M, Carpenter T, Chaussain C, Dandurand K, Filler G, Florenzano P, Fukumoto S, Grasemann C, Imel E, de Beur S, Morgante E, Ward L, Khan A, Guyatt G. Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia. The Journal Of Clinical Endocrinology & Metabolism 2025, 110: 1205-1217. PMID: 39787354, PMCID: PMC12012687, DOI: 10.1210/clinem/dgaf011.Peer-Reviewed Original ResearchX-linked hypophosphatemiaConventional therapyLower limb deformitiesNo treatmentMedical therapyAdverse eventsManagement of "X-linked hypophosphatemiaTreatment-emergent adverse eventsObservational study of individualsObservational studyEfficacy of medical therapyPhysical health QoLAssessed risk of biasBurden of symptomsEffects of medical therapyOpen-label RCTRisk of biasCertainty of evidenceIncreased adverse eventsLimb deformitiesPost hoc studyWeb of ScienceHealth QoLStudy of individualsDental abscessDiuretic Potentiation Strategies in Acute Heart Failure
Siddiqi T, Packer M, Ezekowitz J, Fonarow G, Greene S, Kittleson M, Khan M, Mentz R, Testani J, Voors A, Butler J. Diuretic Potentiation Strategies in Acute Heart Failure. JACC Heart Failure 2025, 13: 14-27. PMID: 39779178, DOI: 10.1016/j.jchf.2024.09.017.Peer-Reviewed Original ResearchConceptsAcute heart failureHeart failureReceptor antagonistSodium-glucose cotransporter 2 inhibitorsLoop diuretic agentsMarkers of congestionMineralocorticoid receptor antagonistsVasopressin receptor antagonistsHeart failure eventsLong-term outcomesShort-term markersCarbonic anhydrase inhibitorsDiuretic strategyThiazide diureticsSerum creatinineDecongestion strategiesClinical outcomesConventional therapyDiuretic agentsImprove symptomsPhysical signsDiureticsCombination strategiesSymptomsAntagonist
2024
Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia
Ali D, Mirza R, Alsarraf F, Hussein S, Abu Alrob H, Appelman-Dijkstra N, Beck-Nielsen S, Biosse-Duplan M, Brandi M, Carpenter T, Chaussain C, Cohen-Solal M, Crowley R, Dandurand K, Florenzano P, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Imel E, de Beur S, Lehman A, Lewiecki E, Morgante E, Ward L, Khan A, Guyatt G. Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia. The Journal Of Clinical Endocrinology & Metabolism 2024, 110: 1767-1780. PMID: 39715351, PMCID: PMC12086399, DOI: 10.1210/clinem/dgae890.Peer-Reviewed Original ResearchX-linked hypophosphatemiaConventional therapyPatient-important outcomesNo treatmentModerate certaintyObservational studyAdult patientsManagement of "X-linked hypophosphatemiaEfficacy of medical therapyEffects of burosumabLow certaintyObservational study of individualsHigh-certainty evidenceAssessed risk of biasRisk of biasAbscess riskLow RoB.Medical therapyImprove painPain measuresBurosumabWeb of ScienceGRADE methodologyTherapyEvidence certaintySAT-283 Tumor-Induced Osteomalacia Disease Monitoring Program: A Longitudinal Cohort Study on An Ultra-Rare Disease
De Beur S, Dahir K, Imel E, Zanchetta M, Li J, Hetzer J, Ciğeroğlu O, Carpenter T. SAT-283 Tumor-Induced Osteomalacia Disease Monitoring Program: A Longitudinal Cohort Study on An Ultra-Rare Disease. Journal Of The Endocrine Society 2024, 8: bvae163.2316. PMCID: PMC12047137, DOI: 10.1210/jendso/bvae163.2316.Peer-Reviewed Original ResearchTumor-induced osteomalaciaGroup 1Group 2Group 3Burosumab treatmentTreatment of tumor-induced osteomalaciaData cutoff dateDiagnosis to enrollmentSafety of burosumabComplete surgical removalRenal phosphate wastingHuman monoclonal antibodyEfficacy of burosumabLong-term safetyAge of subjectsTime of enrollmentBone painMean doseLongitudinal cohort studyMesenchymal tumorsSurgical removalMusculoskeletal painClinical manifestationsConventional therapyPhosphate wastingRisankizumab for Ulcerative Colitis
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel J, Parkes G, Peyrin-Biroulet L, D’Haens G, Hisamatsu T, Siegmund B, Wu K, Boland B, Melmed G, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan W, Pivorunas V, Sanchez Gonzalez Y, D’Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus E, Balderramo D, Goncalves S, Lasa J, Novillo A, Ruffinengo O, Heeren S, Reinisch W, Baert F, Bossuyt P, Colard A, Dewit O, Ferrante M, Franchimont D, Louis E, Rahier J, Francesconi C, Kaiser Junior R, Parra R, Sassaki L, Penchev P, Stanchev D, Atkinson K, Beaton M, Bessissow T, Greenbloom S, Lachance J, Lim A, Panaccione R, Samson J, Shulman S, Siffledeen J, Alfaro I, Valenzuela C, Walsen G, An P, Cao Q, Chen Y, Chen Y, Gao X, Hou X, Hu N, Li Y, Liu F, Liu M, Lungen L, Ran Z, Tang T, Wang X, Yang S, Zhan Q, Zhang G, Zhang H, Zhang J, Zhang X, Zhong J, Zou X, Alvarez E, Ricaurte J, Borzan V, Krznaric Z, Puljiz Z, Bortlik M, Svoboda P, Ulbrych J, Vanasek T, Kjeldsen J, Munck L, Poulsen A, Ali E, Salem O, Sawah H, Waked I, Altwegg R, FLAMANT M, Fumery M, Hebuterne X, Laharie D, Peyrin-Biroulet L, Roblin X, Treton X, Atreya R, Deppe H, Hasselblatt P, Kandulski A, Klaus J, Krause T, Kucharzik T, Mertens J, Mross M, Naumann A, Reindl W, Schiefke I, Schreiber S, Schubert S, Siegmund B, Sturm A, Bamias G, Koutroubakis I, Manolakopoulos S, Mantzaris G, Tzouvala M, Viazis N, Avni-Biron I, Goldin E, Katz L, Lahat-Zok A, Segal A, Ardizzone S, Armuzzi A, Cicala M, Colecchia A, Cosintino R, Gasbarrini A, Geccherle A, Giannini E, Gionchetti P, Luzza F, Monteleone G, Privitera A, Saibeni S, Vangeli M, Abe Y, Aoyama N, Asonuma K, Endo Y, Esaki M, Fujii T, Fukuda K, Hirai F, Hisanaga Y, Horiki N, Iguchi M, Ishigami K, Ishiguro Y, Ito H, Kakuta Y, Kamikozuru K, Kato J, Kawanishi T, Kobayashi T, Kuge H, Maemoto A, Masuda T, Matsuoka K, Matsushima K, Matsushima M, Motoya S, Nakai K, Nakajima K, Nakamura M, Nishida A, Nishikawa T, Nishimata N, Ochiai T, Ohmiya N, Ohnishi Y, Oka S, Ozeki K, Saito D, Saruta M, Sasaki M, Shimizu M, Sugimoto K, Sujino T, Suzuki T, Takatori H, Takatsu N, Takedatsu H, Takeuchi K, Tanaka H, Tokito S, Endo T, Toyokawa T, Uenoyama Y, Yamamoto T, Yamamoto T, Yasuda H, Yokoyama K, Derovs A, Pukitis A, Jonaitis L, Kazenaite E, Pinzon Te L, D'Haens G, Lutgens M, Brooker J, Gearry R, Griffiths B, Inns S, Schultz M, Eszyk J, Kierkus J, Kleczkowski D, Kopon A, Petryka R, Regula J, Romanczyk T, Rydzewska-Wyszkowska G, Sikorski P, Talarek M, Cerqueira R, Goncalves T, Lopes S, Ministro P, Portela F, Tavares H, Diculescu M, Goldis A, Seicean A, Agafina A, Edin A, Gerasimova E, Gettueva M, Kashnikov V, Pirmagomedov A, Rafalskiy V, Sharapova K, Smolyarchuk E, Varganova D, Grgov S, Jovanovic I, Svorcan P, Tarabar D, Ling K, Balaz J, Durina J, Gregus M, Laclav M, Drobne D, Deetlefs E, Peter J, Rajabally M, Rosa J, van Zyl J, Wright J, Cheon J, Jang B, Kim J, Kang S, Kim D, Kim T, Kim Y, Lee J, Lee K, Park D, Song G, Arguelles Arias F, Castro Laria L, Echarri Piudo A, Garcia Lopez S, Hernandez Ramirez V, Martin Arranz M, Varela Trastoy P, Vera Mendoza M, Lordal M, Biedermann L, Misselwitz B, Chang C, Chou J, Kuo C, Lin C, Tu C, Alkim H, Erzin Y, Soykan I, Kravchenko T, Tsarynna N, Vyshyvanyuk V, Ahmad T, Cummings F, Kapur K, Kaser A, Kent A, Parkes G, Patel K, Speight R, Steel A, Aberra F, Aguilar H, Al Bawardy B, Ananthakrishnan A, Barnes M, Beck K, Berkelhammer C, Boland B, Bullock J, Chiplunker A, Dalal R, Dalal S, Delgado B, DiGiovanna M, DuVall G, Freedland C, Friedenberg K, Gaidos J, Ginsburg P, Hassanein T, Higgins P, Hong J, Hou J, Huilgol V, Inamdar N, Kapur S, Kerman D, Levine H, Lodhia N, Loftus E, Mayoral J, McNeil D, Melmed G, Mushahwar A, Ojeas H, Patel B, Phillips R, Pouzar J, Sarles H, Schock J, Sedghi S, Shah N, Siddiqui J, Stokesberry D, Su L, Swaminath A, Verma D, Weber J, Younes Z, Zisman T. Risankizumab for Ulcerative Colitis. JAMA 2024, 332: 881-897. PMID: 39037800, PMCID: PMC11264075, DOI: 10.1001/jama.2024.12414.Peer-Reviewed Original ResearchClinical remission rateActive ulcerative colitisRemission rateUlcerative colitisInduction trialsMaintenance trialsClinical centersPhase 3 randomized clinical trialModerately to severely active ulcerative colitisSeverely active ulcerative colitisSafety of risankizumabTreatment of ulcerative colitisHistory of intoleranceMaintenance therapyClinical remissionClinical responseResponse to 1Intravenous treatmentRisankizumabAdverse event signalsConventional therapySubcutaneous treatmentFollow-upPlaceboAdvanced therapiesTesting in functional constipation—What's new and what works
Rodriguez L. Testing in functional constipation—What's new and what works. Alimentary Pharmacology & Therapeutics 2024, 60: s30-s41. PMID: 38940015, DOI: 10.1111/apt.17857.Peer-Reviewed Original ResearchColonic manometryFecal incontinenceConventional therapyRadiopaque markersFunctional constipationNon-retentive fecal incontinenceDiagnostic studiesFailed medical therapyLumbar spine MRIRecto-anal inhibitory reflexAnal resting pressureAbdominal X-raySpine MRIAnorectal manometryMedical therapyPaediatric constipationSurgical interventionClinical findingsInhibitory reflexEvaluate anatomySpinal abnormalitiesColonic transitMedical historyPaediatric gastroenterologistsConstipationManagement of postinfectious inflammatory arthritis
Baker H, Amaral J, Schoen R. Management of postinfectious inflammatory arthritis. Current Opinion In Rheumatology 2024, 36: 155-162. PMID: 38411201, DOI: 10.1097/bor.0000000000001009.Peer-Reviewed Original ResearchConceptsTreatment of acute infectionsAcute infectionInflammatory arthritisBenefits of antimicrobial therapyTreatment of infectionsTargeted synthetic DMARDsSpectrum of diseasesRefractory arthritisAntimicrobial therapySynthetic DMARDsFraction of casesTreatment optionsConventional therapyDisease-modifying treatmentsReactive arthritisInflammatory arthritidesInflammatory processPrompt identificationSelf-limitingChronic arthritisArthritisInfectionTreatmentTherapyArthralgia
2023
Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease
Kirk F, Munk D, Swenson E, Quicquaro A, Vendelbo M, Larsen A, Schilsky M, Ott P, Sandahl T. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease. Journal Of Hepatology 2023, 80: 586-595. PMID: 38081365, DOI: 10.1016/j.jhep.2023.11.023.Peer-Reviewed Original ResearchEffect of tetrathiomolybdateWilson's diseaseBiliary copper excretionBiliary excretionHealthy volunteersCopper excretionWD patientsBis-choline tetrathiomolybdateNeurologic Wilson diseaseClinical trial numberPresent human studyTrial numberPET/CTCopper metabolismIntestinal copper uptakeMechanism of actionPET/MRINeurological worseningConventional therapyVenous bloodClinical trialsLower riskAnimal studiesHuman studiesCopper chelatorGamma knife capsulotomy for intractable OCD: Neuroimage analysis of lesion size, location, and clinical response
McLaughlin N, Magnotti J, Banks G, Nanda P, Hoexter M, Lopes A, Batistuzzo M, Asaad W, Stewart C, Paulo D, Noren G, Greenberg B, Malloy P, Salloway S, Correia S, Pathak Y, Sheehan J, Marsland R, Gorgulho A, De Salles A, Miguel E, Rasmussen S, Sheth S. Gamma knife capsulotomy for intractable OCD: Neuroimage analysis of lesion size, location, and clinical response. Translational Psychiatry 2023, 13: 134. PMID: 37185805, PMCID: PMC10130137, DOI: 10.1038/s41398-023-02425-2.Peer-Reviewed Original ResearchConceptsY-BOCS reductionObsessive-compulsive disorderGamma knife capsulotomyLesion sizeRefractory obsessive-compulsive disorderOverall lesion volumeIntractable obsessive-compulsive disorderLesion-symptom mappingVoxel-wise lesion-symptom mappingClinical improvementClinical responseWhite matter pathwaysClinical outcomesFull respondersConventional therapyInternal capsuleLesion characteristicsLesion volumeAnterior limbEffective treatmentLesion locationLesion occurrenceCoronal planeSize/locationPatients
2022
Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma
Kenworthy C, Di M, Deshpande H. Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. Current Problems In Cancer Case Reports 2022, 8: 100202. DOI: 10.1016/j.cpccr.2022.100202.Peer-Reviewed Original ResearchNatural killer (NK) cell activityImmune checkpoint inhibitor therapyImmune checkpoint inhibitor useSoluble IL-2 receptorCheckpoint inhibitor useImmune checkpoint inhibitorsCheckpoint inhibitor therapyCoffee-ground emesisIL-2 receptorPelvic osteosarcomaCheckpoint inhibitorsElevated ferritinInhibitor therapyHemophagocytic lymphohistiocytosisMetastatic sarcomaFailed treatmentElevated triglyceridesInhibitor useSarcoma patientsConventional therapyCell activationCancer treatmentPatientsSarcomaTherapyInduction and Maintenance Treatment of Lupus Nephritis: A Comprehensive Review of Meta-Analyses
Shin J, Li H, Park S, Yang J, Lee K, Jo Y, Park S, Oh J, Kim H, An H, Jeong G, Jung H, Lee H, Kim J, Nam S, Koyanagi A, Jacob L, Hwang J, Yon D, Lee S, Tizaoui K, Kronbichler A, Kim J, Smith L. Induction and Maintenance Treatment of Lupus Nephritis: A Comprehensive Review of Meta-Analyses. Journal Of Clinical Medicine 2022, 11: 343. PMID: 35054037, PMCID: PMC8780781, DOI: 10.3390/jcm11020343.Peer-Reviewed Original ResearchComprehensive review of meta-analysesLupus nephritisEnd stage kidney diseaseSystemic lupus erythematosusCalcineurin inhibitorsTreatment of lupus nephritisMeta-analysesReview of meta-analysesEvidence of therapyMMF-treated patientsRates of remissionStage kidney diseaseNetwork meta-analysesPartial remissionMaintenance therapyInfectious complicationsImmunomodulatory therapyRelapse rateLupus erythematosusMaintenance treatmentConventional therapyLN managementComparative efficacyKidney diseaseTherapeutic approaches
2021
Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve
Butala NM, Secemsky E, Kazi DS, Song Y, Strom JB, Faridi KF, Brennan JM, Elmariah S, Shen C, Yeh RW. Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve. JACC Cardiovascular Interventions 2021, 14: 2112-2123. PMID: 34620389, PMCID: PMC8855223, DOI: 10.1016/j.jcin.2021.08.006.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacement (TAVR) trialsReal-world patientsReal-world populationTrial patientsPivotal trialsClinical practiceTreatment effectsReplacement trialsAbsolute reductionClinical practice findingsU.S. clinical practiceCharacteristics of patientsCongestive heart failureTrial treatment effectPatient characteristicsTrial cohortHeart failureMedicare cohortAbsolute benefitConventional therapyClinical trialsInverse probability weightingMedicare patientsTAVRMedicare beneficiaries
2020
Response of the ENPP1‐Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice
Ferreira CR, Kavanagh D, Oheim R, Zimmerman K, Stürznickel J, Li X, Stabach P, Rettig RL, Calderone L, MacKichan C, Wang A, Hutchinson HA, Nelson T, Tommasini SM, von Kroge S, Fiedler IA, Lester ER, Moeckel GW, Busse B, Schinke T, Carpenter TO, Levine MA, Horowitz MC, Braddock DT. Response of the ENPP1‐Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice. Journal Of Bone And Mineral Research 2020, 36: 942-955. PMID: 33465815, PMCID: PMC8739051, DOI: 10.1002/jbmr.4254.Peer-Reviewed Original ResearchConceptsBone mineral densityLow bone mineral densityTrabecular bone massBone massEarly-onset osteoporosisAsj/Conventional therapyLower trabecular bone massGreater bone fragilityRisk of nephrocalcinosisHigh-phosphate dietLow bone massCortical bone massDevelopment of nephrocalcinosisBone biomechanical propertiesAcademic medical centerPlasma phosphorus concentrationsAutosomal recessive hypophosphatemic ricketsRecessive hypophosphatemic ricketsENPP1 deficiencyRachitic phenotypeMedullary nephrocalcinosisRenal failureNormal chowMineral densityEvaluation of Fecal Incontinence in Pediatric Functional Constipation
Morera C, Nurko S, Rodriguez L. Evaluation of Fecal Incontinence in Pediatric Functional Constipation. Journal Of Pediatric Gastroenterology And Nutrition 2020, 72: 361-365. PMID: 33560756, DOI: 10.1097/mpg.0000000000002978.Peer-Reviewed Original ResearchConceptsPediatric functional constipationFecal incontinenceFunctional constipationColonic manometryMedian anal resting pressureAnal resting pressureMore patientsResting pressureAbnormal studiesConventional therapyMale genderTreatment outcomesClinical dataConstipationNormal studiesTherapy responseMeal responseIncontinencePatientsMultivariate analysisMotility studiesTherapyNormal armLow responseManometryHypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway
Lu Y, Liu Y, Oeck S, Zhang GJ, Schramm A, Glazer PM. Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway. Cancer Research 2020, 80: 4655-4667. PMID: 32873635, PMCID: PMC7642024, DOI: 10.1158/0008-5472.can-20-1192.Peer-Reviewed Original ResearchMeSH KeywordsAcrylamidesAniline CompoundsAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell HypoxiaCell Line, TumorDrug Resistance, NeoplasmHumansLung NeoplasmsMAP Kinase Signaling SystemMiceProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 1Up-RegulationXenograft Model Antitumor AssaysConceptsEGFR tyrosine kinase inhibitorsTyrosine kinase inhibitorsEpithelial-mesenchymal transitionNon-small cell lung cancer (NSCLC) cell line H1975Fibroblast growth factor receptor 1 expressionMEK inhibitorsNSCLC cell line H1975EGFR-TKI resistanceEGFR-TKI osimertinibOverexpression of FGFR1Receptor 1 expressionEGFR-TKI sensitivityExpression of FGFR1Lung cancer cellsAttractive therapeutic strategyMAPK pathwayProapoptotic factor BimClinical efficacyConventional therapyDevelopment of resistanceEGFR mutationsSelective small molecule inhibitorsTKI resistanceKnockdown of FGFR1Therapeutic strategiesLong‐term Use of Bisacodyl in Pediatric Functional Constipation Refractory to Conventional Therapy
Bonilla S, Nurko S, Rodriguez L. Long‐term Use of Bisacodyl in Pediatric Functional Constipation Refractory to Conventional Therapy. Journal Of Pediatric Gastroenterology And Nutrition 2020, 71: 288-291. PMID: 32459741, DOI: 10.1097/mpg.0000000000002795.Peer-Reviewed Original ResearchConceptsConventional therapyLong-term usePediatric constipationFunctional constipationSide effectsTertiary care children's hospitalFrequency of BMPediatric functional constipationBowel movement frequencyLong-term followLong-term treatmentMedian doseRescue therapyMedian durationStandard therapyOsmotic laxativesRetrospective reviewPediatric populationChildren's HospitalStimulant laxativesMedian numberConstipationPatientsTreatment durationFavorable response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply